The Role of ETNPPL in Dopaminergic Neuron Stability: Insights from Neuromelanin-Associated Protein Expression in Parkinson’s Disease DOI Open Access
Francesca A. Schillaci, Giuseppe Lanza, Maria Grazia Salluzzo

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(23), P. 13107 - 13107

Published: Dec. 6, 2024

More than six million people worldwide are affected by Parkinson's disease (PD), a multifactorial disorder characterized the progressive loss of dopaminergic neurons in substantia nigra pars compacta (SNc). Several immunohistochemical studies suggest that neuromelanin (NM), found these neurons, plays key role their degeneration. In this study, twelve formalin-fixed, paraffin-embedded (FFPE) brain sections were analyzed, comprising samples from PD patients and healthy controls. Immunohistochemistry (IHC) was conducted to assess expression ETNPPL protein samples. detected both control Additionally, we examined mRNA using Quantitative Real-Time PCR (qRT-PCR) same sample set. Notably, samples, closely associated with dark NM pigment cytoplasm SNc neurons. contrast, showed weak cytoplasmic ETNPPL, no association pigment. No nuclear signal either or qRT-PCR results revealed lower individual compared Importantly, observed higher concentration at level controls, consistent patterns. These findings potential for normal function underscore its altered disease.

Language: Английский

Porous Materials for Early Diagnosis of Neurodegenerative Diseases DOI Creative Commons
Payam Arghavani, Hossein Daneshgar, Soheil Sojdeh

et al.

Advanced Healthcare Materials, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 6, 2025

Abstract Neurodegenerative diseases, particularly Alzheimer's disease and Parkinson's disease, present formidable challenges in modern medicine due to their complex pathologies the absence of curative treatments. Despite advances symptomatic management, early diagnosis remains essential for mitigating progression improving patient outcomes. Traditional diagnostic methods, such as MRI, PET, cerebrospinal fluid biomarker analysis, are often inadequate detection these diseases. Emerging porous materials, including metal–organic frameworks (MOFs), covalent–organic (COFs), MXene, zeolites, silicon, offer promising new approaches neurodegenerative These characterized by highly tunable physicochemical properties, have potential capture concentrate disease‐specific biomarkers amyloid‐beta (Aβ), tau protein, alpha‐synuclein (α‐Syn). The integration materials into advanced biosensors real‐time holds promise revolutionizing neurodiagnostic, enabling non‐invasive, sensitive, specific platforms. Furthermore, incorporation artificial intelligence (AI) machine learning (ML) techniques analysis sensor data enhances accuracy allows more efficient interpretation profiles. AI ML can optimize feature selection, improve pattern recognition, facilitate prediction progression, making them indispensable tools personalized medicine. This review explores diagnostics, emphasizing design, functionality, synergistic role advancing clinical applications.

Language: Английский

Citations

1
Electrochemical biosensor based on gold nanoparticles/laser induced graphene for diagnosis of Parkinson’s disease by detecting phosphorylated α-synuclein in human blood DOI Creative Commons
Seongeun Jeong, Sangheon Park, Seungmin Lee

et al.

Chemical Engineering Journal, Journal Year: 2025, Volume and Issue: unknown, P. 161329 - 161329

Published: March 1, 2025

Language: Английский

Citations

1
An α-helical peptide-based plasmonic biosensor for highly specific detection of α-synuclein toxic oligomers DOI Creative Commons

Juliana Fátima Giarola,

Jaime Santos, M.‐Carmen Estévez

et al.

Analytica Chimica Acta, Journal Year: 2024, Volume and Issue: 1304, P. 342559 - 342559

Published: March 30, 2024

α-Synuclein (αS) aggregation is the main neurological hallmark of a group neurodegenerative disorders, collectively referred to as synucleinopathies, which Parkinson's disease (PD) most prevalent. αS oligomers are elevated in cerebrospinal fluid (CSF) PD patients, standing biomarker for diagnosis. However, methods early detection still lacking. We have recently identified amphipathic 22-residue peptide PSMα3 high-affinity binder toxic oligomers. displayed excellent selectivity and reproducibility, binding with affinities low nanomolar range without detectable cross-reactivity functional monomeric αS. In this work, we leveraged these unique properties design plasmonic-based biosensor direct under label-free conditions. describe integration lab-on-a-chip plasmonic platform suitable point-of-care measurements CSF samples real-time at an affordable cost, providing innovative diagnosis clinic.

Language: Английский

Citations

6
Application of Nanobiosensor Engineering in the Diagnosis of Neurodegenerative Disorders DOI Creative Commons

Thikra S. Dhahi,

Alaa Kamal Yousif Dafhalla, A. Wesam Al-Mufti

et al.

Results in Engineering, Journal Year: 2024, Volume and Issue: 24, P. 102790 - 102790

Published: Sept. 5, 2024

Language: Английский

Citations

6
A Surface Imprinted Polymer EIS Sensor for Detecting Alpha-Synuclein, a Parkinson’s Disease Biomarker DOI Creative Commons
Roslyn S. Massey,

Rishabh Ramesh Appadurai,

Ravi Prakash

et al.

Micromachines, Journal Year: 2024, Volume and Issue: 15(2), P. 273 - 273

Published: Feb. 15, 2024

Parkinson’s Disease (PD) is a debilitating neurodegenerative disease, causing loss of motor function and, in some instances, cognitive decline and dementia those affected. The quality life can be improved, disease progression delayed through early interventions. However, current methods confirming PD diagnosis are extremely invasive. This prevents their use as screening tool for the onset stages PD. We propose surface imprinted polymer (SIP) electroimpedance spectroscopy (EIS) biosensor detecting α-Synuclein (αSyn) its aggregates, biomarker that appears saliva blood during blood-brain barrier degrades. stamp fabricated by low-temperature melt stamping polycaprolactone (PCL) on interdigitated EIS electrodes. result low-cost, small-footprint highly suitable non-invasive monitoring biomarker. sensors were tested with αSyn dilutions deionized water constant ionic concentration matrix solutions decreasing concentrations to remove background effects concentration. device response confirmed specificity these devices target protein monomeric αSyn. sensor limit detection was measured 5 pg/L, linear range pg/L–5 µg/L. covers physiological makes this promising method quantifying monomers patients future. SIP regenerated, reused demonstrate capability repeat sensing potential continuous

Language: Английский

Citations

5
Exploring faradaic and non-faradaic electrochemical impedance spectroscopy approaches in Parkinson's disease diagnosis DOI Creative Commons

Hussaini Adam,

Subash C. B. Gopinath, Tijjani Adam

et al.

Heliyon, Journal Year: 2024, Volume and Issue: 10(5), P. e27433 - e27433

Published: March 1, 2024

Parkinson's disease is a neurodegenerative condition defined by the progressive death of dopaminergic neurons in brain. The diagnosis often uses time-consuming clinical evaluations and subjective assessments. Electrochemical Impedance Spectroscopy (EIS) useful technique for electroanalytical devices due to its label-free performance, in-situ measurements, low cost. development reliable diagnostic tools can be significantly enhanced exploring novel techniques like faradaic non-faradaic EIS detection methods. These have ability identify specific biomarkers or changes electrochemical properties linked disease, allowing an early accurate diagnosis. Faradaic methods utilize redox processes on electrode surface, while rely charge transfer capacitive properties. electrical as indicators measuring impedance at different frequencies. By combining both approaches, it may possible obtain comprehensive understanding occurring patients. This lead more effective potentially opening up new avenues personalized treatment strategies. review explores current research approaches diagnosing using spectroscopy.

Language: Английский

Citations

5
Current trends in blood biomarkers detection and neuroimaging for Parkinson's disease DOI
Ni Liu, Tianjiao Zhang, Wei Zhao

et al.

Ageing Research Reviews, Journal Year: 2025, Volume and Issue: unknown, P. 102658 - 102658

Published: Jan. 1, 2025

Language: Английский

Citations

0
An rGO-doped laser induced graphene electrochemical biosensor for highly sensitive exosome detection DOI Creative Commons
Xiaohong Chen,

Xiaohui Yan,

Jiaoyan Qiu

et al.

Sensors & Diagnostics, Journal Year: 2024, Volume and Issue: 3(10), P. 1724 - 1732

Published: Jan. 1, 2024

An electrochemical biosensing chip using rGO-modified LIG was developed to detect exosomes for breast cancer diagnostics.

Language: Английский

Citations

3
Metallic Nanomaterials in Parkinson's Disease: A Transformative Approach for Early Detection and Targeted Therapy DOI Creative Commons
Amira I. Mansour,

Mariam Hossam Eldin,

Ibrahim M. El‐Sherbiny

et al.

Journal of Materials Chemistry B, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

This review article illustrates and discusses the application of metallic nanomaterials (MNMs) in detection treatment PD, as well theranostic MNMs.

Language: Английский

Citations

0
Recent Advances in Electrochemical Biosensors for Neurodegenerative Disease Biomarkers DOI Creative Commons

Minkun Bae,

Nayoung Kim, Euni Cho

et al.

Biosensors, Journal Year: 2025, Volume and Issue: 15(3), P. 151 - 151

Published: Feb. 28, 2025

Neurodegenerative diseases, such as Parkinson’s disease (PD) and Alzheimer’s (AD), represent a growing global health challenge with overlapping biomarkers. Key biomarkers, including α-synucleins, amyloid-β, Tau proteins, are critical for accurate detection but often assessed using conventional methods like enzyme-linked immunosorbent assay (ELISA) polymerase chain reaction (PCR), which invasive, costly, time-intensive. Electrochemical biosensors have emerged promising tools biomarker due to their high sensitivity, rapid response, potential miniaturization. The integration of nanomaterials has further enhanced performance, improving specificity, practical application. To this end, review provides comprehensive overview recent advances in electrochemical detecting neurodegenerative highlighting strengths, limitations, future opportunities. By addressing the challenges early diagnosis, work aims stimulate interdisciplinary innovation improve clinical outcomes patients.

Language: Английский

Citations

0